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Abstract
Background: The Xpert MTB/RIF test (GeneXpert) has recently been endorsed for use in resource-limited settings for the
diagnosis of tuberculosis and drug resistant-tuberculosis. In resource-limited settings, GeneXpert has been used
predominantly for research and there is little experience with its use in day-to-day management of patients.
Case summary: We describe a case of  a 46 year old HIV-infected male with smear-negative pulmonary tuberculosis, who
had several visits to various lower level health centres and two admissions in a tertiary care hospital; however, the diagnosis
of tuberculosis was only made several months later on GeneXpert testing that was performed under a research project.
Conclusion:  GeneXpert facilitated identification of tuberculosis in an HIV positive patient in whom the diagnosis had
been delayed when more widely available tests were used. Operational and cost-effectiveness studies are needed to provide
evidence to policy makers in order to improve access to GeneXpert.
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Introduction
Early treatment of tuberculosis (TB) is hindered by
the lack of rapid, accurate diagnostic modalities that
can be applied in resource-limited settings (RLS)1-2.
Sputum smear microscopy1 which is the cheapest
and the most available method of TB diagnosis
identifies TB in less than half of patients with HIV/
TB co-infection. Access to mycobacterial culture is
limited and where available results are often delayed
by several weeks. Xpert MTB/RIF test (GeneXpert)
is a promising innovation in routine TB diagnosis in
developing countries owing to the its high sensitivity,
specificity and rapid turnaround time of only two
hours3-6. GeneXpert is an integrated fully automated
specimen processing and nucleic-acid-amplification
test3-4  that was recently endorsed for use in RLS by
the World Health Organization for the diagnosis of
MTB and drug resistant-TB. However, its roll-out is
hampered by the relatively high cost of the machine,
need to import diagnostic cartridges and need for
constant and stable electricity supply 5. We present a
case highlighting the clinical use of this test in a high
burden TB setting.
Case summary
A 46 year old Ugandan male truck driver presented
to the medical wards of Mulago National Referral
Hospital in January 2012 with productive cough, low
grade fevers and left-sided chest pain of six weeks’
duration. Prior to this visit, he had made several visits
to health providers in lower level health centres for
the same illness and received unknown oral antibiotics
with no improvement. He had no previous history
of  TB and was a non-smoker.  His HIV serology
test was positive. Although smear microscopy
examinations performed on two sputum samples
were negative for acid fast bacilli (AFB), his chest
radiograph revealed consolidation in the left mid and
lower lung zones (figure 1a). He was treated for
bacterial pneumonia with cephalosporins (ceftriaxone
1gram given intravenously at 12 hourly for 5 days),
followed by a macrolide  (azithromycin tablets 500mg
every 24 hours for 3 days) and discharged a week
later on cotrimoxazole prophylaxis, referred for HIV
care and scheduled for follow-up one month later.
However, three weeks after discharge, he returned
to hospital with worsening cough, fever, weight loss
and anorexia. On examination, he was febrile
(temperature 37.9æ% C), wasted (body mass index
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=16.2kg/m2), dehydrated and pale. He was
tachypneic (respiratory rate 30 breathes/min) and
still had features of left consolidation.
Laboratory investigations findings included
significantly low CD4 count (21cells/µl), raised ESR
(80mm/hr), mild leucopenia (WBC count
3.42X103cells/µl) with normal differential counts,
normochromic anemia (9.2g/dl), hypoalbuminemia
(18.2g/l) and normal serum chemistries. His chest
radiograph (figure 1b) revealed signs of persisting
consolidation but repeat smear microscopy exams
were negative for AFB. Bacterial blood cultures were
negative, mycobacterial cultures were not performed
as they are not part of the routine TB diagnostic
work up for this hospital. Abdominal ultrasound
scan showed micro liver abscesses.
The patient showed no changes in signs and
symptoms after 2 weeks on admission and treatment
with intravenous fluids and antibiotics which included
ceftriaxone 1gram given intravenously every twelve
hours daily for one week. GeneXpert testing was
performed under a research project (since the test
was not readily available in this hospital) and this
detected mycobacterium tuberculosis that was sensitive
to Rifampicin. The patient was commenced on anti-
TB therapy in accordance with Uganda guidelines
and he showed significant improvement.  He was
discharged a week later and subsequently
commenced antiretroviral therapy (tenofovir
disoproxil fumarate, emtricitabine plus efavirenz).
The patient continues to be well.
1a
Figure 1: Chest radiographs taken one month
apart showing consolidation (arrow) involving
the left lower and mid lung zones
1b
Discussion
This case illustrates the diagnostic difficulties
encountered in the management of sputum smear-
negative TB in a setting of high HIV/TB prevalence
and the clinical benefit of GeneXpert. The HIV
epidemic has led to an increase in the incidence of
smear-negative pulmonary TB and such cases are
increasingly common1 in RLS. Smear-negative
pulmonary TB is associated with poor treatment
outcomes, including death due to delayed diagnosis
or non-diagnosis1-2. New technologies like
GeneXpert provide an opportunity for early
identification of TB5, 7,8, 9 which could reduce
morbidity and mortality in smear- negative TB
patients. GeneXpert is a promising new test in routine
TB diagnosis in developing countries owing to its
high sensitivity, specificity and rapid turnaround time3-
6. It is an integrated specimen processing and nucleic-
acid-amplification test which is fully automated and
offers results in only two hours3-4. In all settings,
GeneXpert test has consistently demonstrated better
performance5-8  when compared to smear
microscopy and its performance compares well with
liquid culture. The assay is also highly specific since
there is no cross-reaction with non-tuberculous
mycobacteria3-4. Furthermore, the performance of
GeneXpert is not affected by HIV co infection 6. In
a multi-country study6 (including Uganda), the
sensitivity of GeneXpert testing was 90·3% among
culture-confirmed TB cases, 76·9% among smear-
negative, culture-positive TB patients and the
specificity was 99·0%.
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The cost of a GeneXpert test compares
favourably to mycobacterial culture but it has the
distinct advantage of a faster turn-around time,
providing same-day diagnosis which could potentially
limit loss to follow up during diagnostic evaluation
of  smear- negative TB patients2, 6, 9. Furthermore,
GeneXpert testing implementation may be cost
saving both to the patient and the health system 5, 6, 9.
GeneXpert testing could potentially reduce the costs
associated with clinic visits, drugs, hospital
admissions and chest x-rays as well as TB associated
morbidity and mortality. From the health system
point of  view, implementation of  GeneXpert testing
could potentially reduce physician consultations,
hospital bed occupancy, transmission and antibiotic
use. However, formal cost-effectiveness studies on
GeneXpert have not been conducted in Uganda.
Mycobacterial cultures are the gold standard
for TB diagnosis but were not performed for the
patient in this report because this is not standard of
care for new TB suspects at our centre. Culture
results are often obtained several weeks after samples
are collected and therefore, a diagnostic delay would
also be expected with this method.
Conclusion
GeneXpert facilitated identification of TB in this HIV
positive patient in whom the diagnosis had been
delayed when more widely available tests were used.
However, operational and cost-effectiveness studies
are needed within the local context to support
allocation of resources to expand access to innovative
technologies like GeneXpert.
Consent
Informed consent was obtained from the patient
for publication of this case report and any
accompanying images.
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